Multiple Sclerosis News Today

FDA approves generic injection to help manage MS

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Healthline

Copaxone and Pregnancy, Breastfeeding, and Birth Control

Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...
Healthline

Dosage for Copaxone: What You Need to Know

Copaxone is available in two strengths: 20 milligrams (mg) per 1 milliliter (mL) of liquid solution and 40 mg/mL. The drug comes in single-dose prefilled syringes for injection under the skin. For all ...
FierceBiotech

Teva Announces Copaxone® Reaches One Million Patient Years of Experience in the Treatment of Multiple Sclerosis

Approved in 1996, Copaxone ® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
News Medical

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) ...
FierceBiotech

Treatment with COPAXONE® in Multiple Sclerosis Demonstrated Remyelination and Neuroprotective Effects in a Preclinical Set

Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
Business Wire

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis: COBRA study presented at the 7th Congress ...

AMSTERDAM--(BUSINESS WIRE)--The COBRA study, a new real world evidence study undertaken by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and St. Josef Hospital (Bochum, Germany), was ...
Business Wire

New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE

“ The results are consistent with the previously published analysis of this Markov model, which evaluated use of COPAXONE ® and the beta interferons compared to symptom management alone for the ...